荃信生物-B（江蘇荃信生物醫藥股份有限公司，股票代码：02509）于2026年7月17日发布公告，披露公司于香港联交所场内回购1000股普通股H股。该批股份占回购前已发行股本的约0.00045%，每股回购价为每股15.99港元，涉资总额约1.60万港元。本次回购股份将被持作库藏股。
公告显示，经本次变动后，公司已发行股份总数仍为227,071,600股，其中在外流通股数为223,369,200股，库藏股数则增至3,702,400股。本次回购依据公司于2026年5月29日通过的股份回购授权进行，公司可根据授权回购总数达22,436,340股，截至目前累计已回购994,200股，占授权通过当日已发行股本约0.4431%。公司确认其回购行为符合香港联合交易所有限公司证券上市规则及相关法律规定。
上述公告由董事会秘书和联席公司秘书胡衍保签署。公司表示，将继续关注市场状况，并在授权范围内适度且审慎地实施股份回购。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.